# Implementation of a Randomized, Placebo-Controlled Trial of Live Attenuated Malaria Sporozoite Vaccines in an Indonesian Military Study Population

**Authors:** Khoriah Indrihutami, Krisin Chand, Rizka Fahmia, Mutia Rahardjani, Fitria Wulandari, Decy Subekti, Rintis Noviyanti, Amin Soebandrio, Noch T. Mallisa, I Made Mardika, Waras Budiman, Irwan Suriswan, Yogi Ertanto, Mei-Chun Chen, Tooba Murshedkar, Yonas Abebe, B. Kim Lee Sim, Stephen L. Hoffman, Thomas L. Richie, Sky Chen, Iqbal R. F. Elyazar, Lenny L. Ekawati, J. Kevin Baird, Erni J. Nelwan

PMC · DOI: 10.4269/ajtmh.23-0597 · 2024-03-26

## TL;DR

This paper describes a trial testing malaria vaccines in Indonesian soldiers before deployment to a high-risk area.

## Contribution

The study presents a novel approach to vaccine testing in a military population with unique logistical challenges.

## Key findings

- The trial involved 345 soldiers vaccinated before a 6,000-km journey to a malaria-prone region.
- Key to success was stakeholder communication and adaptability to unexpected events.
- The trial highlights the complexities of conducting such research in a military context.

## Abstract

Malaria eradication efforts prioritize safe and efficient vaccination strategies, although none with high-level efficacy against malaria infection are yet available. Among several vaccine candidates, Sanaria® PfSPZ Vaccine and Sanaria PfSPZ-CVac are, respectively, live radiation- and chemo-attenuated sporozoite vaccines designed to prevent infection with Plasmodium falciparum, the leading cause of malaria-related morbidity and mortality. We are conducting a randomized normal saline placebo-controlled trial called IDSPZV1 that will analyze the safety, tolerability, immunogenicity, and efficacy of PfSPZ Vaccine and PfSPZ-CVac administered pre-deployment to malaria-naive Indonesian soldiers assigned to temporary duties in a high malaria transmission area. We describe the manifold challenges of enrolling and immunizing 345 soldier participants at their home base in western Indonesia before their nearly 6,000-km voyage to eastern Indonesia, where they are being monitored for incident P. falciparum and Plasmodium vivax malaria cases during 9 months of exposure. The unique regulatory, ethical, and operational complexities of this trial demonstrate the importance of thorough planning, frequent communication, and close follow-up with stakeholders. Effective engagement with the military community and the ability to adapt to unanticipated events have proven key to the success of this trial.

## Linked entities

- **Diseases:** malaria (MONDO:0005136)
- **Species:** Plasmodium falciparum (taxon 5833), Plasmodium vivax (taxon 5855)

## Full-text entities

- **Diseases:** infection (MESH:D007239), Malaria (MESH:D008288)
- **Chemicals:** Live Attenuated Malaria Sporozoite (-)
- **Species:** Plasmodium vivax (malaria parasite P. vivax, species) [taxon 5855], Plasmodium falciparum (malaria parasite P. falciparum, species) [taxon 5833]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11066349/full.md

---
Source: https://tomesphere.com/paper/PMC11066349